Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in graves' ophthalmopathy

Bernadett Ujhelyi, Annamaria Erdei, L. Galuska, J. Varga, Lajos Szabados, Erzsebet Balazs, Miklos Bodor, Bela Cseke, Z. Karányi, Andras Leovey, E. Mezősi, Kenneth D. Burman, A. Berta, E. Nagy

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: In Graves' ophthalmopathy (GO), only patients with immunologically active disease respond to immunosuppressive therapy. Previous studies and theoretical considerations suggest that elevated orbital 99mTc-diethylenetriamine-pentaacetic-acid (DTPA) single photon emission computed tomography (SPECT) reflects inflammatory disease activity. We studied whether corticosteroid treatment causes a substantial decrease in DTPA uptake in GO, a result consistent with successful immunosuppressive treatment of GO and referred to as a favorable treatment outcome. Methods: One hundred fourteen orbits in 57 patients with active GO (CAS ≥ 4) were entered into the study. All patients received corticosteroid treatment. Orbital DTPA uptakes were numerically quantified for the entire orbit as well as the anterior and posterior segments separately. DTPA SPECT was performed before, and 2 to 9 months after the initiation of immunosuppressive treatment. The normal range for DTPA uptake was established in 34 orbits of 17 patients who were being worked up for Raynaud's phenomenon and had no thyroid disease. Results: The mean DTPA uptake of the 114 orbits of GO patients was higher prior to corticosteroid therapy than after this treatment (11.03 ± 4.26 MBq/cm 3 and 9.84 ± 3.51 MBq/cm 3, respectively, p <0.001) but a substantial decline in DTPA uptake was seen in only 39.5% of GO patients. The positive predictive value of an initial DTPA >12.28 MBq/cm 3 for a substantial decline in DTPA uptake (favorable treatment outcome) was 76%, while a negative predictive value of a pretreatment DTPA ≤12.28 MBq/cm 3 was 78%. Conclusions: Corticosteriod treatment is associated with a decline in DTPA uptake in a fraction of GO patients. GO patients with a DTPA uptake above 12.28 MBq/cm 3 are more likely to have a favorable response to corticosteroid therapy while patients with lower values are less likely to have this potentially favorable response. An elevated DTPA uptake may identify patients who are most likely to benefit from immunosuppressive treatment.

Original languageEnglish
Pages (from-to)375-380
Number of pages6
JournalThyroid
Volume19
Issue number4
DOIs
Publication statusPublished - Apr 1 2009

Fingerprint

Graves Ophthalmopathy
Pentetic Acid
Immunosuppressive Agents
Orbit
Adrenal Cortex Hormones
Therapeutics
Single-Photon Emission-Computed Tomography
Raynaud Disease
Thyroid Diseases
Reference Values
Theoretical Models

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in graves' ophthalmopathy. / Ujhelyi, Bernadett; Erdei, Annamaria; Galuska, L.; Varga, J.; Szabados, Lajos; Balazs, Erzsebet; Bodor, Miklos; Cseke, Bela; Karányi, Z.; Leovey, Andras; Mezősi, E.; Burman, Kenneth D.; Berta, A.; Nagy, E.

In: Thyroid, Vol. 19, No. 4, 01.04.2009, p. 375-380.

Research output: Contribution to journalArticle

Ujhelyi, Bernadett ; Erdei, Annamaria ; Galuska, L. ; Varga, J. ; Szabados, Lajos ; Balazs, Erzsebet ; Bodor, Miklos ; Cseke, Bela ; Karányi, Z. ; Leovey, Andras ; Mezősi, E. ; Burman, Kenneth D. ; Berta, A. ; Nagy, E. / Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in graves' ophthalmopathy. In: Thyroid. 2009 ; Vol. 19, No. 4. pp. 375-380.
@article{79ebf06836904f538a164df4ab473fe8,
title = "Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in graves' ophthalmopathy",
abstract = "Background: In Graves' ophthalmopathy (GO), only patients with immunologically active disease respond to immunosuppressive therapy. Previous studies and theoretical considerations suggest that elevated orbital 99mTc-diethylenetriamine-pentaacetic-acid (DTPA) single photon emission computed tomography (SPECT) reflects inflammatory disease activity. We studied whether corticosteroid treatment causes a substantial decrease in DTPA uptake in GO, a result consistent with successful immunosuppressive treatment of GO and referred to as a favorable treatment outcome. Methods: One hundred fourteen orbits in 57 patients with active GO (CAS ≥ 4) were entered into the study. All patients received corticosteroid treatment. Orbital DTPA uptakes were numerically quantified for the entire orbit as well as the anterior and posterior segments separately. DTPA SPECT was performed before, and 2 to 9 months after the initiation of immunosuppressive treatment. The normal range for DTPA uptake was established in 34 orbits of 17 patients who were being worked up for Raynaud's phenomenon and had no thyroid disease. Results: The mean DTPA uptake of the 114 orbits of GO patients was higher prior to corticosteroid therapy than after this treatment (11.03 ± 4.26 MBq/cm 3 and 9.84 ± 3.51 MBq/cm 3, respectively, p <0.001) but a substantial decline in DTPA uptake was seen in only 39.5{\%} of GO patients. The positive predictive value of an initial DTPA >12.28 MBq/cm 3 for a substantial decline in DTPA uptake (favorable treatment outcome) was 76{\%}, while a negative predictive value of a pretreatment DTPA ≤12.28 MBq/cm 3 was 78{\%}. Conclusions: Corticosteriod treatment is associated with a decline in DTPA uptake in a fraction of GO patients. GO patients with a DTPA uptake above 12.28 MBq/cm 3 are more likely to have a favorable response to corticosteroid therapy while patients with lower values are less likely to have this potentially favorable response. An elevated DTPA uptake may identify patients who are most likely to benefit from immunosuppressive treatment.",
author = "Bernadett Ujhelyi and Annamaria Erdei and L. Galuska and J. Varga and Lajos Szabados and Erzsebet Balazs and Miklos Bodor and Bela Cseke and Z. Kar{\'a}nyi and Andras Leovey and E. Mezősi and Burman, {Kenneth D.} and A. Berta and E. Nagy",
year = "2009",
month = "4",
day = "1",
doi = "10.1089/thy.2008.0298",
language = "English",
volume = "19",
pages = "375--380",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in graves' ophthalmopathy

AU - Ujhelyi, Bernadett

AU - Erdei, Annamaria

AU - Galuska, L.

AU - Varga, J.

AU - Szabados, Lajos

AU - Balazs, Erzsebet

AU - Bodor, Miklos

AU - Cseke, Bela

AU - Karányi, Z.

AU - Leovey, Andras

AU - Mezősi, E.

AU - Burman, Kenneth D.

AU - Berta, A.

AU - Nagy, E.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Background: In Graves' ophthalmopathy (GO), only patients with immunologically active disease respond to immunosuppressive therapy. Previous studies and theoretical considerations suggest that elevated orbital 99mTc-diethylenetriamine-pentaacetic-acid (DTPA) single photon emission computed tomography (SPECT) reflects inflammatory disease activity. We studied whether corticosteroid treatment causes a substantial decrease in DTPA uptake in GO, a result consistent with successful immunosuppressive treatment of GO and referred to as a favorable treatment outcome. Methods: One hundred fourteen orbits in 57 patients with active GO (CAS ≥ 4) were entered into the study. All patients received corticosteroid treatment. Orbital DTPA uptakes were numerically quantified for the entire orbit as well as the anterior and posterior segments separately. DTPA SPECT was performed before, and 2 to 9 months after the initiation of immunosuppressive treatment. The normal range for DTPA uptake was established in 34 orbits of 17 patients who were being worked up for Raynaud's phenomenon and had no thyroid disease. Results: The mean DTPA uptake of the 114 orbits of GO patients was higher prior to corticosteroid therapy than after this treatment (11.03 ± 4.26 MBq/cm 3 and 9.84 ± 3.51 MBq/cm 3, respectively, p <0.001) but a substantial decline in DTPA uptake was seen in only 39.5% of GO patients. The positive predictive value of an initial DTPA >12.28 MBq/cm 3 for a substantial decline in DTPA uptake (favorable treatment outcome) was 76%, while a negative predictive value of a pretreatment DTPA ≤12.28 MBq/cm 3 was 78%. Conclusions: Corticosteriod treatment is associated with a decline in DTPA uptake in a fraction of GO patients. GO patients with a DTPA uptake above 12.28 MBq/cm 3 are more likely to have a favorable response to corticosteroid therapy while patients with lower values are less likely to have this potentially favorable response. An elevated DTPA uptake may identify patients who are most likely to benefit from immunosuppressive treatment.

AB - Background: In Graves' ophthalmopathy (GO), only patients with immunologically active disease respond to immunosuppressive therapy. Previous studies and theoretical considerations suggest that elevated orbital 99mTc-diethylenetriamine-pentaacetic-acid (DTPA) single photon emission computed tomography (SPECT) reflects inflammatory disease activity. We studied whether corticosteroid treatment causes a substantial decrease in DTPA uptake in GO, a result consistent with successful immunosuppressive treatment of GO and referred to as a favorable treatment outcome. Methods: One hundred fourteen orbits in 57 patients with active GO (CAS ≥ 4) were entered into the study. All patients received corticosteroid treatment. Orbital DTPA uptakes were numerically quantified for the entire orbit as well as the anterior and posterior segments separately. DTPA SPECT was performed before, and 2 to 9 months after the initiation of immunosuppressive treatment. The normal range for DTPA uptake was established in 34 orbits of 17 patients who were being worked up for Raynaud's phenomenon and had no thyroid disease. Results: The mean DTPA uptake of the 114 orbits of GO patients was higher prior to corticosteroid therapy than after this treatment (11.03 ± 4.26 MBq/cm 3 and 9.84 ± 3.51 MBq/cm 3, respectively, p <0.001) but a substantial decline in DTPA uptake was seen in only 39.5% of GO patients. The positive predictive value of an initial DTPA >12.28 MBq/cm 3 for a substantial decline in DTPA uptake (favorable treatment outcome) was 76%, while a negative predictive value of a pretreatment DTPA ≤12.28 MBq/cm 3 was 78%. Conclusions: Corticosteriod treatment is associated with a decline in DTPA uptake in a fraction of GO patients. GO patients with a DTPA uptake above 12.28 MBq/cm 3 are more likely to have a favorable response to corticosteroid therapy while patients with lower values are less likely to have this potentially favorable response. An elevated DTPA uptake may identify patients who are most likely to benefit from immunosuppressive treatment.

UR - http://www.scopus.com/inward/record.url?scp=66749137527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66749137527&partnerID=8YFLogxK

U2 - 10.1089/thy.2008.0298

DO - 10.1089/thy.2008.0298

M3 - Article

C2 - 19355827

AN - SCOPUS:66749137527

VL - 19

SP - 375

EP - 380

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 4

ER -